REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
13 hedge funds and large institutions have $35.4M invested in REVIVA PHARMA HLDGS INC in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 6 closing their positions.
6% more capital invested
Capital invested by funds: $33.5M → $35.4M (+$1.87M)
1.16% more ownership
Funds ownership: 2.04% → 3.19% (+1.2%)
19% less funds holding
Funds holding: 16 → 13 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$5.08M |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$2.6M |
| 3 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$1.88M |
| 4 |
Walleye Trading
New York
|
+$491K |
| 5 |
CAC
Cowen and Company
New York
|
+$265K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$4.94M |
| 2 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
-$1.29M |
| 3 |
GF
Gabelli Funds
Rye,
New York
|
-$1.09M |
| 4 |
AGM
Alpine Global Management
New York
|
-$690K |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$422K |
RVPH Hedge Fund Activity: Q3 2020 in Review
13 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q3 2020, worth a combined $35.4M — up 5.6% from $33.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RVPH and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Glazer Capital LLC, adding an estimated $5.08M. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $4.94M sold.
- 13 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q3 2020, down from 16 in Q2 2020.
- Funds reported $35.4M of REVIVA PHARMA HLDGS INC stock for Q3 2020, up 5.6% quarter-over-quarter.
- 3 funds opened new REVIVA PHARMA HLDGS INC positions in Q3 2020 and 6 closed out, a net change of -3 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q3 2020 was Glazer Capital LLC, an estimated $5.08M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q3 2020 was Polar Asset Management Partners, an estimated $4.94M sold.
Based on aggregated 13F filings for Q3 2020.